Obinutuzumab + Glofitamab + Gemcitabine + Oxaliplatin
Phase 2Recruiting 0 views this week 0 watching⚡ Active
Interest: 42/100
42
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
B-Cell Non-Hodgkins Lymphoma
Conditions
B-Cell Non-Hodgkins Lymphoma
Trial Timeline
Mar 5, 2025 → Mar 30, 2029
NCT ID
NCT06806033About Obinutuzumab + Glofitamab + Gemcitabine + Oxaliplatin
Obinutuzumab + Glofitamab + Gemcitabine + Oxaliplatin is a phase 2 stage product being developed by Roche for B-Cell Non-Hodgkins Lymphoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06806033. Target conditions include B-Cell Non-Hodgkins Lymphoma.
What happened to similar drugs?
3 of 20 similar drugs in B-Cell Non-Hodgkins Lymphoma were approved
Approved (3) Terminated (2) Active (15)
Hype Score Breakdown
Clinical
12
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06806033 | Phase 2 | Recruiting |
Competing Products
20 competing products in B-Cell Non-Hodgkins Lymphoma